ADHD Clinical Trials 2023
ADD studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect adhd clinical trial in 2023.
Open Labelfor Attention Deficit Hyperactivity Disorder (ADHD)
Cohort 1: SDX/d-MPH In 4-5 Year Oldfor Attention Deficit Hyperactivity Disorder (ADHD)
Managing Challenging Behaviors In ADHDfor Psychosocial Intervention
Academic Accommodationsfor Attention Deficit Hyperactivity Disorder (ADHD)
Be Unstoppable In Life Together (BUILT)for Attention Deficit Hyperactivity Disorder (ADHD)
Centanafadine Hydrochloridefor Attention Deficit Hyperactivity Disorder (ADHD)
Animal Assisted Interventionfor Attention Deficit Hyperactivity Disorder (ADHD)
I2-ART Groupfor Attention Deficit Hyperactivity Disorder (ADHD)
Mega Team - Video Gamefor Congenital Heart Disease
What is ADHD?
Attention deficit hypersensitivity disorder, also known as ADHD, is a common neurodevelopmental disorder that develops in children. The disorder occurs in 5.9% of preadolescents and 2.9% of adults. People with ADHD exhibit signs of inattentiveness, hyperactivity, and impulsivity during their childhood and, in some cases, even in their adulthood. Its legitimate cause is unknown—however, most cases of ADHD list genetics and environmental factors as its main cause. Today, more findings and developments are being made by world-renowned medical experts in ADHD clinical trials.
Why is ADHD being studied in clinical trials?
The exact cause of ADHD is still unknown. Even though ADHD is extensively researched, much is yet to be discovered. Today, many medications and treatments are being used in clinical trials that could potentially show valuable results.
How do ADHD clinical trials work?
Each ADHD clinical trial has different processes and results. It is formed in phases and may span over a long period of time. ADHD clinical trials typically test the effectiveness of medication or some form of treatment on its participants. One such example is the study entitled “Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD”, which is a clinical trial that is presently being researched in Baltimore, Maryland.
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD is a study from the John Hopkins School of Medicine that seeks to determine whether methylphenidate can alter the brain activity of people diagnosed with ADHD. The study tests the combination of methylphenidate and placebo in adults with ADHD while calculating the changes in task-related neural activity and brain glutamate levels. Its goal is to advance neuroimaging biomarkers in predicting methylphenidate treatment response, leading to new novel pharmacological treatments.
A total of thirty participants are intended to participate in the study. The participants will be divided into two treatment groups: the experimental treatment group or the methylphenidate first group and the non-treatment group or the placebo first group. Each participant will be given one oral dose of methylphenidate or placebo, depending on which treatment group they belong to. After dose intake, the participants will be subjected to neuropsychological testing and brain scans. The results of this study will lead to developments in pharmacological treatments for ADHD If deemed successful.
What are some key breakthrough clinical trials involving ADHD?
It has taken many years for ADHD to become recognized, studied, and properly understood. As of late, there have been multiple ADHD clinical trials that have propagated efficient results, namely:
2005: Therapeutic Response - The results of this study show that vigorous amounts of methylphenidate are effective in adults with ADHD. Response to the methylphenidate treatment was higher than that of the placebo treatment and was unharmful to the participants.
2006: Adderall Efficacy - The results of this study show that a daily dose of 10-40mg/d of mixed amphetamine salts extended-release (MAS XR) to adolescents with ADHD have a considerable development in their symptoms compared to placebo.
Who are the key opinion leaders on ADHD clinical trial research?
Stephen Faraone, Ph.D., is a senior investigator of psychiatry from Mass General Research Institute, a research staff of psychiatry from Massachusetts General Hospital, and a part-time lecturer on psychology in the department of psychiatry at Harvard Medical school. He was the 2nd most-cited author of ADHD in 2005 and has written over 800 books, editorials, and journal articles.
Philip Asherson, Ph.D., is an emeritus professor of neurodevelopmental psychiatry at King’s College London. His research mainly focuses on ADHD, clinical and genetic studies of ADHD, neurodevelopmental disorders, and neuropsychiatric disorders.
Top Hospitals For ADHD Clinical Trials
Power’s data revealed that the top hospital actively performing ADHD clinical trials is Massachusetts General Hospital in Boston, Massachusetts. It recorded its first clinical trial in 2001, and it has since continued to perform clinical trials. Presently, there are six trials that are active and ongoing, which are: Solriamfetol 150 MG for Attention Deficit Disorder, SMS Intervention for Attention Deficit Disorder, SMS Intervention for Attention Deficit Disorder, SMS Intervention for Attention Deficit Hyperactivity Disorder (ADHD), MRI for Attention Deficit Hyperactivity Disorder (ADHD), and Transcranial Photobiomodulation for Autism, Early Infantile.
Massachusetts General Hospital is known for being the third oldest general hospital in the United States, having been built in 1811. The U.S. News & World Report has continuously ranked Massachusetts General Hospital among the top five hospitals in the United States. The hospital has 25,000 employees, which include 5,000 registered nurses, 4,500 allied health workers, 2,400 physicians, and 2,300 research scientists.
ADHD clinical trials are also being actively conducted at the following hospitals: The Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas, Nevada, The Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio, The Seattle Children's Hospital in Seattle, Washington, and MindPath Care Centers in Raleigh, North Carolina.
Top Treatments for ADHD Clinical Trials
The top treatment for ADHD clinical trials is short message service (SMS) intervention. It was first recorded in 2016. There are three active ADHD trials currently being performed, which are: SMS Intervention for Attention Deficit Disorder, SMS Intervention for Attention Deficit Disorder, and SMS Intervention for Attention Deficit Hyperactivity Disorder (ADHD).
Top treatments for ADHD clinical trials include methylphenidate, AKL-T01, weight-based low-dose centanafadine capsules, and CLS-R-Fuerte.
Top Cities for ADHD Clinical Trials
Las Vegas, located in Nevada, is the top city for ADHD clinical trials. Among the top cities for ADHD clinical trials are Cincinnati, New York, Boston, and Seattle. Eight clinical trials are actively being performed at the Center for Psychiatry and Behavioral Medicine, Inc. These trials are SPN-812 for Hyperkinesis, SPN-812 for Hyperkinesis, AKL-T01 for Attention Deficit Disorder, Open-Label Treatment for Attention Deficit Disorder, 15 mg Aptensio XR for Attention Deficit Hyperactivity Disorder (ADHD), ADHD Therapy for Attention Deficit Hyperactivity Disorder (ADHD), AKL-T01 for Attention Deficit Disorder, Guanfacine hydrochloride (TAK-503) for Attention Deficit Hyperactivity Disorder (ADHD).
Which phases are most popular for ADHD clinical trials?
The most popular phase for ADHD clinical trials is Phase < 1. Among the most popular phases are Phase 1, Phase 1 and 2, Phase 2, Phase 2 and 3, Phase 3, and Phase 4. You can see more clinical trials in their different Phases of development here.
How many ADHD clinical trials are open to youth and/or seniors?
There are a total of seventy-two ADHD clinical trials that are available to youth and/or seniors. Thirty-six active trials are available to people of the age of eighteen or under. Ten active trials are available to people aged eighteen or older. Sixteen active trials are available to participants that are within the age of eighteen and sixty-five. Six active trials are available to people that are aged under sixty-five. And only four active trials are open to participants of any age.